



Commercial/Healthcare Exchange Quantity Limit Criteria *Effective: November 7th, 2018*

Prior Authorization: Mektovi

Products Affected: Mektovi (binimetinib) oral tablets

Medication Description:

Mektovi (binimetinib) is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK 2 activity. Binimetinib has inhibited extracellular signal-related kinase (ERK) phosphorylation and viability and MEK-dependent phosphorylation of BRAF- mutant human melanoma cell lines in vitro. In vivo it has also inhibited ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models.

Mektovi is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Covered Uses: Malignant melanoma, unresectable or metastatic, with a BRAF V600E or V600K mutation, in combination with encorafenib

Exclusion Criteria: Left ventricular ejection fraction < 50%

Required Medical Information:

1. Diagnosis
2. BRAF mutation status
3. Previous therapies tried

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with, an oncologist

Coverage Duration:

Initial: 12 months

Continuation: 3 years

Other Criteria:

Mektovi (binimetinib) will be approved for the following diagnosis when the subsequent criteria are met:

1. Patient is 18 year of age or older; **AND**
2. Patient has a diagnosis of malignant melanoma; **AND**
3. Patient's disease is unresectable or metastatic; **AND**
4. Presence of BRAF V600E or V600K mutation has been confirmed by and FDA approved test; **AND**

Last Res. July 1st, 2019



Confidential Information

This document is confidential and proprietary to Emblemhealth. Unauthorized use and distribution are prohibited.



5. Mektovi (binimetinib) will be used in combination with Braftovi (encorafenib); **AND**
6. Patient has a left ventricular ejection fraction $\geq 50\%$; **AND**
7. Mektovi (binimetinib) is prescribed by, or in consultation with, an oncologist.

References:

1. Mektovi [package insert]. Boulder, CO; Array BioPharma; June 2018.

Policy Revision history

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|--------------|-----------------------|---|--------------------------|-------------|
| 1 | New Policy | New Policy | All | 11/7/18 |
| 2 | Update | Added continuation coverage duration of 3 years | Coverage Duration | 7/1/2019 |